Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
Jennifer R SchroederKarran A PhillipsDavid H EpsteinMichelle L JobesMelody A FurnariAshley P KennedyMarkus HeiligKenzie L PrestonPublished in: Psychopharmacology (2018)
clinicaltrials.gov identifier: NCT01517165.
Keyphrases